Best in Biotech 27 Dec 2017 The Biggest Biotech News of 2017: What Happened This Year? Still catching up on news? We’ve picked out the most exciting things that happened besides clinical results and finance. Here’s the biggest biotech news of 2017. We’ve been recapping the year with the most stellar biotechs, most heartening clinical successes and most disappointing failures in biotech. But what else happened this year? There’s more news […] December 27, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Dec 2017 Interviews, Reviews and Tops: Our Best Biotech Articles from 2017 We love hearing from our readers, and we listen to what they like! Here are the long reads from our best biotech articles of 2017. We gave you a list of books to read this holiday season, but do you need something lighter for the post-Christmas daze? We’ve collected our most popular long articles of […] December 26, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2017 Biota Beats: Music from the Microbiome Bacteria and music are two completely unrelated concepts for most of us. But not for the group of artists and scientists behind Biota Beats. The iGEM synthetic biology competition gathers teams of enthusiastic students every year in Boston. But this year, it also gathered the bacteria of the participants. The team from Biota Beats asked […] December 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2017 Scientists Find New Immune Target to Stop Progression of Alzheimer’s Scientists have described a new mechanism by which the immune system can drive Alzheimer’s and shown that blocking it can prevent the disease in mice. A study published yesterday in Nature details how a molecule involved in the innate immune response can promote the aggregation of amyloid-β plaques that appear in the brains of patients […] December 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2017 Oxford Biotech Makes a Latin American Deal for Its Antibiotic In a deal worth up to €23.6M, Summit Therapeutics licensed the commercialization of its new antibiotic ridinilazole to Eurofarma. Oxford-based Summit Therapeutics is working on new antibiotics to fight antimicrobial resistance. Its candidate ridinilazole has attracted the attention of a Brazilian pharma, Eurofarma, and the pair has made a deal for $2.5M (€2.1M) upfront and […] December 21, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Inside Labiotech 21 Dec 2017 How Labiotech is Surfing on the Digital Media Revolution Media was the first industry to be disrupted by the digital revolution, aka “The Internet”. Most of the established media platforms are still trying to figure out what to do, especially on the revenues/profits side of things. On the other hand, some of the biggest players today were founded in the last 15 years, think […] December 21, 2017 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2017 Britain’s Life Science Strategy: What UK Biotech Can Do From the Bottom Up Britain has been making a concerted effort to grow its biotech sector, especially after Brexit. What’s the plan and what can UK biotech do? The last time I walked the the echoey corridors of the Palace of Westminster (UK parliament), I was a wee twelve-year old, on a mission to push forward legislation to prevent […] December 21, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 Israeli Biotech Acquires Microbiome Company to Fight Chronic Liver Disease BiomX has acquired RondinX, expanding its bacterial target discovery platform and adding new microbiome targets for chronic liver disease. BiomX is a company based in Ness Ziona, Israel, developing customized phage therapy to selectively destroy the bacteria that cause diseases ranging from inflammatory bowel disease (IBD) to cancer. The company has just acquired RondinX, another […] December 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 British Gene Therapy Gets a Huge £85M Boost in Series B Orchard Therapeutics has raised a big round of financing to gene therapy options for many rare diseases for which there are no treatments. London-based Orchard Therapeutics has managed to raise £85M (€96M) in Series B, an amount that will certainly give an important boost to its pipeline of gene therapy treatments for rare diseases. The […] December 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […] December 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 Christmas Has Come Early for Nordic Biotechs as a Norwegian Fund Readies €100M Injection Hadean Ventures has closed its first fund, which it will begin to invest in life sciences companies around Europe, particularly in the Nordic region. Hadean Ventures is a VC fund based in Oslo, Norway, with the aim of improving healthcare to help patients that are suffering around the world. The VC has closed Hadean Capital […] December 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 How to Deal with Regulations to Get Approval for CAR-T Cells The biotech industry is diving into the field of highly individualized gene and cell therapy products. The first CAR-T therapy has just been approved in the US and other breakthrough technologies like mRNA and CRISPR have a foot in the door. But getting to the market is not straightforward, not only for developers but also for […] December 20, 2017 - 8 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email